DEI/Health Equity

1

Date of Presentation

5-2-2024 12:00 AM

College

Rowan-Virtua School of Osteopathic Medicine

Poster Abstract

Aims

This review aims to assess the correlations between outcomes and cost of treatment methods for pediatric acute lymphoblastic leukemia patients, specifically comparing CAR T-cell therapy and Standard-of-Care (SoC) therapy. The socioeconomic background of patients will also be taken into consideration to see if there are differences in their outcomes.

Methods

Peer-reviewed publications were collected from PubMed and Web of Science. The keyword strings used were “acute lymphoblastic leukemia,” “pediatric acute lymphoblastic leukemia,” “pediatric,” “CAR T-cell therapy,” and “cost-effectiveness.” 27 citations were obtained. Titles were screened by 6 authors. Articles met the inclusion criteria including potential Quality-Adjusted Life Year (QALY) gains, mean price of CAR T-cell therapy and SoC therapy. The outcomes measured were presented in terms of total treatment cost for both CAR T-cell therapy and SoC treatments such as chemotherapy and/or hematopoietic stem-cell transplant.

Results

In the 6 comparative studies used, the overall cost and QALY of CAR T-cell therapy was higher than the SoC. In 4 of 6 studies, the price per QALY for CAR T-cell therapy was lower than the SoC treatment, ranging from $24,696 - $304,611 less per QALY. In the other 2 studies, the price per QALY for CAR T-cell therapy was higher by $6,452 and $18,874 per QALY.

Conclusions

Overall, CAR T-cell therapy was more expensive; however, it provided more QALY than other SoC’s. Future studies could determine if and how socioeconomic status, region, and race impact QALY for CAR T-cell, and how to mitigate barriers to access.

Keywords

CAR T-cell therapy, Tisagenlecleucel therapy, Standard of Care, acute lymphoblastic leukemia, treatment outcomes, socioeconomic factors, cost-effectiveness, quality-adjusted life years, child, pediatric

Disciplines

Health and Medical Administration | Hemic and Lymphatic Diseases | Inequality and Stratification | Medicine and Health | Medicine and Health Sciences | Oncology | Other Analytical, Diagnostic and Therapeutic Techniques and Equipment | Pediatrics | Therapeutics

Document Type

Poster

DOI

10.31986/issn.2689-0690_rdw.stratford_research_day.171_2024

Share

COinS
 
May 2nd, 12:00 AM

Cost-Effectiveness and Outcomes of Utilizing Tisagenlecleucel Therapy (CAR T-cell) in Pediatric Acute Lymphoblastic Leukemia in Comparison to Standard of Care (SoC) Therapies: A Scoping Review

Aims

This review aims to assess the correlations between outcomes and cost of treatment methods for pediatric acute lymphoblastic leukemia patients, specifically comparing CAR T-cell therapy and Standard-of-Care (SoC) therapy. The socioeconomic background of patients will also be taken into consideration to see if there are differences in their outcomes.

Methods

Peer-reviewed publications were collected from PubMed and Web of Science. The keyword strings used were “acute lymphoblastic leukemia,” “pediatric acute lymphoblastic leukemia,” “pediatric,” “CAR T-cell therapy,” and “cost-effectiveness.” 27 citations were obtained. Titles were screened by 6 authors. Articles met the inclusion criteria including potential Quality-Adjusted Life Year (QALY) gains, mean price of CAR T-cell therapy and SoC therapy. The outcomes measured were presented in terms of total treatment cost for both CAR T-cell therapy and SoC treatments such as chemotherapy and/or hematopoietic stem-cell transplant.

Results

In the 6 comparative studies used, the overall cost and QALY of CAR T-cell therapy was higher than the SoC. In 4 of 6 studies, the price per QALY for CAR T-cell therapy was lower than the SoC treatment, ranging from $24,696 - $304,611 less per QALY. In the other 2 studies, the price per QALY for CAR T-cell therapy was higher by $6,452 and $18,874 per QALY.

Conclusions

Overall, CAR T-cell therapy was more expensive; however, it provided more QALY than other SoC’s. Future studies could determine if and how socioeconomic status, region, and race impact QALY for CAR T-cell, and how to mitigate barriers to access.

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.